Key result
NT-proBNP-guided therapy did not reduce the composite of heart failure hospitalization or cardiovascular mortality compared with usual care in high-risk patients with HFrEF.
Why the study?
Smaller studies evaluating natriuretic peptide-guided heart failure therapy have yielded inconsistent results.
Does natriuretic peptide-guided therapy reduce hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction?
RCT (n=894)
Open-label
1:1 simple randomization
Yes
Does natriuretic peptide-guided therapy reduce hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction?
Answers are grounded in this paper and cite their sources.
NP-guided HF therapy yields no outcome benefit; challenges smaller inconsistent studies and supports usual care.
The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels (“guided therapy”) with inconsistent results.
No takes yet. Share an insight, caveat, or question.
Adams et al. (2020) conducted an RCT in Heart failure with reduced ejection fraction (HFrEF) (n=894). NT-proBNP-guided therapy vs. Usual care was evaluated on Composite of time-to-first HF hospitalization or cardiovascular mortality (HR 0.98, 95% CI 0.79-1.22, p=.88). NT-proBNP-guided therapy did not reduce the composite of heart failure hospitalization or cardiovascular mortality compared with usual care in high-risk patients with HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: